Key result
PDA stenting is emerging as a potential first-line alternative to the modified Blalock-Taussig-Thomas shunt for palliating ductal-dependent cyanotic newborns, with comparable or lower risks based on observational data.
Why the study?
To provide a historical review and current perspective on procedures used to palliate cyanosis in ductal-dependent infants as first-line therapy may be shifting from surgical shunts to PDA stenting.
This historical review highlights the evolution of palliation for cyanotic congenital heart disease, suggesting a paradigm shift from the surgical Blalock-Taussig-Thomas shunt to transcatheter PDA stenting.
Historical review of BTT shunt origins informs PDA stenting choices; extends perspective on ductal-dependent palliation.
This article provides a historical review and a current perspective on the procedures used to palliate cyanosis in ductal-dependent infants. Eighty years ago, Helen Taussig, Alfred Blalock and Vivien Thomas developed the first effective treatment. The Blalock-Taussig-Thomas (BTT) shunt is the historical predecessor of both the contemporary modified BTT shunt and interventional stenting of the Patent Ductus Arteriosus (PDA). The surgical shunt was firmly established therapy before catheterization was born, and PDA stenting was not possible until the technologies designed to address coronary heart disease were developed. The momentum of long-established surgical therapy inhibited clinical development of PDA stenting. Nevertheless, available clinical outcomes, though limited, appear to favor PDA stenting, and first-line therapy may be shifting from the modified BTT shunt to PDA stenting. More definitive data should arise from a randomized controlled trial.
No takes yet. Share an insight, caveat, or question.
John W. Moore (2024) conducted a review in Ductal-dependent cyanotic congenital heart disease. PDA stenting vs. Blalock-Taussig-Thomas shunt was evaluated. PDA stenting is emerging as a potential first-line alternative to the modified Blalock-Taussig-Thomas shunt for palliating ductal-dependent cyanotic newborns, with comparable or lower risks based on observational data.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: